Download PDF
CC BY 4.0 · Indian J Med Paediatr Oncol
DOI: 10.1055/s-0043-1774328
Original Article

Expected Usefulness of Fourth Dose of COVID-19 Vaccine for Patients with Underlying Solid Tumor who Previously Received the Primary Heterologous COVID-19 Vaccine

Sora Yasri
1   KM Center, Bangkok Thailand
,
Viroj Wiwanitkit
2   Department of Biological Science, Joseph Ayobabalola University, Ikeji-Arakeji, Nigeria
3   Department of Community Medicine, Dr. DY Patil Medical College - Dr. D. Y. Patil Vidyapeeth, Pune, Maharashtra, India
› Author Affiliations Funding None.
› Further Information
   Permissions and Reprints

Abstract

Coronavirus disease 2019 (COVID-19) immunization frequently requires two standard doses. Due to the likelihood that the population may lose immunity after receiving a standard mass vaccination and the potential for the introduction of a new strain, several scientists are currently advocating the use of a booster dosage of the vaccine.

The authors of this retrospective study used a clinical model for immune response prediction to forecast how solid cancer patients will respond to the fourth dosage of the COVID-19 immunization. In the case of homologous primary backgrounds, the prospective rates of extension of protective efficacy for using viral vector and messenger ribonucleic acid (mRNA) COVID-19 vaccines for vaccinees with underlying solid tumor are equal to 11.5 and 16.5%, respectively. In the event of heterologous primary backgrounds, the prospective rates of extension of protective efficacy for using viral vector and mRNA COVID-19 vaccines are equal to 2.2 and 7.2%, respectively, for patients with underlying solid cancer. In conclusion, the fourth dose of the COVID-19 vaccine regimen had an effect on the immunogenicity of vaccine recipients with underlying malignancy.

Keywords

COVID-19 - dose - fourth - vaccine - cancer

Patient Consent

This study is a clinical mathematical model study and does not directly deal with patients, and therefore, ethical approval is not applicable, and the consent form is also not applicable.




Publication History

Article published online:
30 January 2024

© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Hsia W. Emerging new coronavirus infection in Wuhan, China: situation in early 2020. Case Study Case Rep 2020; 10 (01) 8-9
    Google Scholar
  • 2 Soleimanpour S, Yaghoubi A. COVID-19 vaccine: where are we now and where should we go?. Expert Rev Vaccines 2021; 20 (01) 23-44
    Google Scholar
  • 3 Shekhar R, Garg I, Pal S, Kottewar S, Sheikh AB. COVID-19 vaccine booster: to boost or not to boost. Infect Dis Rep 2021; 13 (04) 924-929
    Google Scholar
  • 4 Krause PR, Fleming TR, Peto R. et al. Considerations in boosting COVID-19 vaccine immune responses. Lancet 2021; 398 (10308): 1377-1380
    Google Scholar
  • 5 The Lancet Infectious Diseases. COVID-19 vaccine equity and booster doses. Lancet Infect Dis 2021; 21 (09) 1193
    Google Scholar
  • 6 Pappas G, Saloustros E, Boutis A. et al. Vaccine third dose and cancer patients: necessity or luxury?. ESMO Open 2021; 6 (06) 100306
    Google Scholar
  • 7 Lee ARYB, Wong SY, Chai LYA. et al. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. BMJ 2022; 376 (01) e068632
    Google Scholar
  • 8 Sun H, Bu F, Li L, Zhang X, Yan J, Huang T. COVID-19 vaccine response and safety in patients with cancer: an overview of systematic reviews. Front Public Health 2022; 10 (01) 1072137
    Google Scholar
  • 9 Shmueli ES, Lawrence YR, Rahav G. et al. Serological response to a third booster dose of BNT162b2 COVID-19 vaccine among seronegative cancer patients. Cancer Rep 2022; 5 (08) e1645
    Google Scholar
  • 10 Petrelli F, Luciani A, Borgonovo K. et al. Third dose of SARS-CoV-2 vaccine: a systematic review of 30 published studies. J Med Virol 2022; 94 (06) 2837-2844
    Google Scholar
  • 11 Seneviratne SL, Yasawardene P, Wijerathne W, Somawardana B. COVID-19 vaccination in cancer patients: a narrative review. J Int Med Res 2022; 50 (03) 3000605221086155
    Google Scholar
  • 12 Munro APS, Janani L, Cornelius V. et al; COV-BOOST study group. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet 2021; 398 (10318): 2258-2276
    Google Scholar
  • 13 Lee LYW, Ionescu MC, Starkey T. et al; UK Coronavirus Cancer Programme. COVID-19: Third dose booster vaccine effectiveness against breakthrough coronavirus infection, hospitalisations and death in patients with cancer: a population-based study. Eur J Cancer 2022; 175 (11) 1-10
    Google Scholar
  • 14 Goel RR, Painter MM, Lundgreen KA. et al. Efficient recall of Omicron-reactive B cell memory after a third dose of SARS-CoV-2 mRNA vaccine. Cell 2022; 185 (11) 1875-1887.e8
    Google Scholar
  • 15 Shmueli ES, Lawrence YR, Rahav G. et al. Serological response to a third booster dose of BNT162b2 COVID-19 vaccine among seronegative cancer patients. Cancer Rep 2022; 5 (08) e1645
    Google Scholar
  • 16 Shroff RT, Chalasani P, Wei R. et al. Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors. Nat Med 2021; 27 (11) 2002-2011
    Google Scholar
  • 17 Guven DC, Incesu FGG, Yildirim HC. et al. Immunogenicity of two doses of inactive COVID-19 vaccine and third booster dose mRNA vaccine in patients with cancer receiving active systemic therapy. Int J Cancer 2023; 152 (04) 679-685
    Google Scholar
  • 18 Sookaromdee P, Wiwanitkit V. New COVID-19 vaccines, its cost and shelf life: a cost effectiveness analysis. Arch Med Res 2021; 52 (04) 453
    Google Scholar
  • 19 Yasri S, Wiwanitkit V. Expected response to the additional third dose of COVID-19 vaccine based on different complete standard vaccination background. Int J Physiol Pathophysiol Pharmacol 2022; 14 (01) 1-3
    Google Scholar
  • 20 Luangdilok S, Wanchaijiraboon P, Pakvisal N. et al. Immunogenicity after a third COVID-19 mRNA booster in solid cancer patients who previously received the primary heterologous CoronaVac/ChAdOx1 vaccine. Vaccines (Basel) 2022; 10 (10) 1613
    Google Scholar